This site is intended for healthcare professionals

Kite submits sBLA to FDA for Tecartus in adult patients with relapsed or refractory acute lymphoblastic leukemia.

Read time: 1 mins
Last updated:2nd Apr 2021
Published:3rd Apr 2021
Condition: B-Cell Acute Lymphoblastic Leukemia
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest